Qifeng Yang1, Meena S Moran, Bruce G Haffty. 1. Department of Radiation Oncology, Cancer Institute of New Jersey, Robert Wood Johnson Medical School-UMDNJ, 195 Little Albany St., New Brunswick, NJ 08901, USA.
Abstract
BACKGROUND: This study was undertaken to evaluate the prognostic significance of Bcl-2, a apoptosis-related protein, in patients with early stage breast cancer treated with breast conservation treatment (BCT). METHODS: After obtaining IRB approval, 504 patients with early stage breast cancer treated with BCT were entered in this study. The paraffin specimens were constructed into tissue micro-arrays with two-fold redundancy, processed and stained for Bcl-2 antibody. Bcl-2 expression was correlated with other clinicopathological parameters and clinical outcomes. RESULTS: Bcl-2 expression was identified in 116 cases (28%). Bcl-2 expression was positively correlated with both estrogen receptor and progesterone receptor status (P < 0.0001, respectively). Bcl-2 expression was associated with ipsilateral breast tumor recurrence (P = 0.0322, by log-rank test). Multivariate analysis using Cox proportional hazard model showed that Bcl-2 expression still retained significance as an independent prognostic factor for breast recurrence (P = 0.0348). CONCLUSIONS: Bcl-2 expression is highly associated with an increased risk of local recurrence in patients with early stage breast cancer. Immunohistochemical staining of the primary tumor for Bcl-2 might be useful to select optimal treatment options for these patients.
BACKGROUND: This study was undertaken to evaluate the prognostic significance of Bcl-2, a apoptosis-related protein, in patients with early stage breast cancer treated with breast conservation treatment (BCT). METHODS: After obtaining IRB approval, 504 patients with early stage breast cancer treated with BCT were entered in this study. The paraffin specimens were constructed into tissue micro-arrays with two-fold redundancy, processed and stained for Bcl-2 antibody. Bcl-2 expression was correlated with other clinicopathological parameters and clinical outcomes. RESULTS:Bcl-2 expression was identified in 116 cases (28%). Bcl-2 expression was positively correlated with both estrogen receptor and progesterone receptor status (P < 0.0001, respectively). Bcl-2 expression was associated with ipsilateral breast tumor recurrence (P = 0.0322, by log-rank test). Multivariate analysis using Cox proportional hazard model showed that Bcl-2 expression still retained significance as an independent prognostic factor for breast recurrence (P = 0.0348). CONCLUSIONS:Bcl-2 expression is highly associated with an increased risk of local recurrence in patients with early stage breast cancer. Immunohistochemical staining of the primary tumor for Bcl-2 might be useful to select optimal treatment options for these patients.
Authors: Benjamin D Zeitlin; Aaron C Spalding; Marcia S Campos; Naoki Ashimori; Zhihong Dong; Shaomeng Wang; Theodore S Lawrence; Jacques E Nör Journal: Int J Radiat Oncol Biol Phys Date: 2010-08-01 Impact factor: 7.038
Authors: M A Laussmann; E Passante; H Düssmann; J A Rauen; M L Würstle; M E Delgado; M Devocelle; J H M Prehn; M Rehm Journal: Cell Death Differ Date: 2011-04-01 Impact factor: 15.828
Authors: Mathilde S Larsen; Karsten Bjerre; Anita Giobbie-Hurder; Anne-Vibeke Lænkholm; Katrine L Henriksen; Bent Ejlertsen; Anne E Lykkesfeldt; Birgitte B Rasmussen Journal: Acta Oncol Date: 2012-03-30 Impact factor: 4.089
Authors: Ning Zhang; Xiaoyan Li; Kai Tao; Liyu Jiang; Tingting Ma; Shi Yan; Cunzhong Yuan; Meena S Moran; Faming Liang; Bruce G Haffty; Qifeng Yang Journal: BMC Med Genet Date: 2011-04-01 Impact factor: 2.103